G42 and Mubadala announce launch of M42

WAM

G42, an Abu Dhabi-based AI technology holding group, and Mubadala Investment Company have announced the launch of M42, a first-of-its-kind, tech-enabled healthcare company.

M42 combines G42 Healthcare’s medical and data-centric technologies with Mubadala Health’s patient services and facilities to provide personalised, precise, and preventative care.

Led by Hasan Jasem Al Nowais, Group Chief Executive Officer, M42 will look at opportunities for global expansion and partnerships with pharmaceutical, healthcare and health-tech leaders to bring high-quality care to communities around the world.

"We are confident that through our operating companies, M42 will create a future in which dedicated healthcare professionals are empowered by the latest technology to optimise patient outcomes. M42 also represents a platform for us to target international expansion and partner with global peers to solve the world’s most pressing healthcare challenges," he highlighted.

M42 owns a wide portfolio of assets that includes Amana Healthcare, Biogenix Labs, Danat Al Emarat, HealthPoint Hospital, the HealthPlus network of speciality centres, Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Insights Research Organisation & Solutions (IROS), Omics Centre of Excellence and The National Reference Laboratory, among others.

In October 2022, G42 Healthcare and Mubadala Health announced that they had joined forces to create a new, integrated healthcare technology powerhouse.

More from Business